PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1606422
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1606422
The Preimplantation Genetic Diagnosis Market was valued at USD 57.80 Million in 2023 and expanded at a CAGR of 7.80% from 2024 to 2032.
Pre-implantation genetic diagnosis (PGD) is a laboratory technique employed alongside in vitro fertilization (IVF) to minimize the likelihood of transmitting hereditary disorders. The primary motivations for utilizing PGD include the presence of particular single-gene disorders, such as polycystic kidney disease, cystic fibrosis, and sickle cell anemia, as well as chromosomal abnormalities in a parent. Additionally, families may opt for PGD when a relative requires a bone marrow donor, enabling them to conceive a child capable of supplying compatible stem cells.
Preimplantation Genetic Diagnosis Market- Market Dynamics
The rising Prevalence of Genetic Disorders is anticipated to drive the growth of the market
Preimplantation Genetic Diagnosis (PGD) offers a significant solution by enabling the selection of embryos free from certain genetic abnormalities. This emphasis on promoting healthy births encourages an increasing number of couples to incorporate PGD into their reproductive strategies. According to the World Health Organization, genetic disorders and congenital anomalies are present in approximately 2%-5% of all live births, contribute to nearly 30% of pediatric hospital admissions, and are responsible for about 50% of childhood fatalities in developed nations.
Additionally, the expansion of fertility clinics and ongoing advancements in genetic testing technologies may present growth opportunities for the market. However, the high costs associated with PGD services could hinder market expansion.
Preimplantation Genetic Diagnosis Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.80% over the forecast period (2024-2032)
Based on Type segmentation, Aneuploidy was predicted to show maximum market share in the year 2023
Based on Technology segmentation, Polymerase Chain Reaction (PCR) was the leading type in 2023
Based on End-User segmentation, the hospital was the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Preimplantation Genetic Diagnosis Market is segmented based on Type, Technology, End-User, and Region.
The market is segmented into six categories according to Type: Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, and others. The segment about Aneuploidy holds a dominant position within the market. Aneuploidy may result in developmental challenges, miscarriages, or congenital anomalies. Consequently, its identification is essential for families pursuing in vitro fertilization.
The market is classified into three segments according to technology: Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), and additional methods. Polymerase Chain Reaction (PCR) holds a leading position in the market. This robust molecular biology technique is employed to amplify particular DNA sequences, rendering it an essential instrument in genetic testing, such as Preimplantation Genetic Diagnosis (PGD).
The market is segmented into four categories according to End-User: Fertility Centers, Hospitals, Diagnostic Centers, Research Centers, Academic Laboratories, and Others. The hospital sector leads the market. Hospitals offer critical clinical services, such as IVF procedures, which frequently serve as the initial phase in the PGD process. The existence of dedicated reproductive health departments within hospitals improves accessibility to PGD for patients pursuing genetic testing.
Preimplantation Genetic Diagnosis Market- Geographical Insights
North America leads the market expansion, attributed to its cutting-edge medical technologies. This region is recognized for hosting some of the most sophisticated medical technologies and research institutions globally. The substantial investment in innovative genetic testing methods, including next-generation sequencing (NGS) and high-throughput screening techniques, significantly improves the efficiency and precision of PGD, rendering it a favored option among patients and healthcare professionals. The United States is the largest medical device market worldwide, accounting for over 40% of the global medtech sector. Europe closely follows in market presence, while the Asia-Pacific region exhibits considerable growth potential, fueled by increasing infertility rates and advancements in healthcare infrastructure.
The Preimplantation Genetic Diagnosis (PGD) Market presents a competitive environment marked by several prominent participants, technological innovations, and an increasing need for genetic screening services. Organizations focused on genetic testing are essential to the PGD market, offering the requisite technologies and expertise for embryo evaluation. The competitive dynamics within the PGD market are significantly shaped by advancements in technology. Firms that create more effective and precise genetic testing methodologies, including next-generation sequencing (NGS) and multiplex PCR, secure a competitive advantage. Ongoing innovation contributes to enhanced sensitivity and specificity in identifying genetic anomalies.
AUSTIN, Texas Natera, Inc., a prominent global entity in the field of cell-free DNA and genetic testing, has announced that it will unveil new findings regarding its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the upcoming 2024 European Society for Medical Oncology (ESMO) Congress, scheduled for September 13-16 in Barcelona, Spain.